Veronika Hruba
Prague, PR, Czech Republic
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Subcutaneous Infliximab in Refractory Crohn's Disease Patients: A Possible Biobetter?
Journal: Crohn's & colitis 360
Published: November 29, 2023
A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn's disease: an analysis of two propensity score-matched cohorts.
Journal: Scandinavian journal of gastroenterology
Published: March 02, 2022
Cellular and Humoral Immune Responses to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease Patients.
Journal: Journal of Crohn's & colitis
Published: January 16, 2022
Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study.
Journal: Inflammatory bowel diseases
Published: September 18, 2021
Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre.
Journal: Journal of Crohn's & colitis
Published: January 07, 2020
Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis - results from multicenter observational cohort.
Journal: Expert opinion on biological therapy
Published: October 03, 2018
Safety of Anti-TNF-Alpha Therapy During Pregnancy on Long-term Outcome of Exposed Children: A Controlled, Multicenter Observation.
Journal: Inflammatory bowel diseases
Published: August 01, 2018
Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort.
Journal: Expert opinion on drug safety
Published: May 16, 2017
Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.
Journal: Digestive diseases (Basel, Switzerland)
Published: February 02, 2017
Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis.
Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis.
Journal: Journal of Crohn's & colitis
Published: October 21, 2015
Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
Journal: Scandinavian journal of gastroenterology
Published: September 03, 2015
Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease.
Journal: Biologicals : journal of the International Association of Biological Standardization
Published: April 26, 2015
Showing 1-12 of 12
Last Updated: 09/26/2026